Allarity Therapeutics, Inc.
ALLR
$1.52
-$0.16-9.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.73% | 24.33% | 15.21% | 11.67% | 14.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.39% | 0.25% | 0.25% | 0.25% | 0.25% |
| Total Operating Expenses | -26.30% | 12.61% | 1.06% | -7.72% | 2.39% |
| Operating Income | 28.13% | -12.61% | -1.06% | 7.72% | -2.39% |
| Income Before Tax | 54.89% | 19.76% | -111.66% | -93.14% | -110.66% |
| Income Tax Expenses | -- | 100.00% | -577.22% | -577.22% | -559.04% |
| Earnings from Continuing Operations | 54.19% | 18.49% | -106.98% | -88.86% | -105.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.19% | 18.49% | -106.98% | -88.86% | -105.99% |
| EBIT | 28.13% | -12.61% | -1.06% | 7.72% | -2.39% |
| EBITDA | 28.34% | -12.50% | -1.02% | 7.67% | -2.56% |
| EPS Basic | 93.77% | 79.14% | -193.98% | -- | -- |
| Normalized Basic EPS | 87.60% | 50.94% | -8.87% | -- | -- |
| EPS Diluted | 93.77% | 79.14% | -193.98% | -- | -- |
| Normalized Diluted EPS | 87.60% | 50.94% | -8.87% | -- | -- |
| Average Basic Shares Outstanding | 795.91% | 2,105.26% | 6,428.60% | -- | -- |
| Average Diluted Shares Outstanding | 795.91% | 2,105.26% | 6,428.60% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |